LifeSpan Licenses DrugTarget Database to Pfizer

LifeSpan BioSciences last week announced that Pfizer has signed an agreement to license its DrugTarget database.

The multi-year agreement will enable Pfizer to gain access to the database, which includes information on more than 3,200 genes, along with 852 immunohistochemistry reports with localization information on more than 400 potential drug targets.

LifeSpan and Pfizer said they would add targets to the database over time.

Financial details were not disclosed.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Researchers find that historical factors influence which genes are the most highly studied, the Atlantic reports.

The US National Science Foundation's new sexual harassment policy is to go into effect next month, according to Nature News.

Researchers report using genotyping to tie together illegal ivory shipments and trace them back to a handful of cartels, the New York Times reports.

In Nature this week: genomic ancestry analysis of Sardinians, current noncoding mutations in colorectal cancer, and more.